ETHAMIDE
LOE ApproachingNDAORALTABLET
Approved
Oct 1966
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 1h ago · AI intelligence enriched 6d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ETHAMIDE is an oral small-molecule tablet approved in 1966 by AbbVie under NDA classification. The drug's specific mechanism of action and therapeutic indications are not publicly detailed in available data. This legacy product represents a mature therapeutic asset with established clinical use over nearly 60 years.
LOE Approaching
Product approaching loss of exclusivity with moderate competitive pressure (30/100), suggesting transition planning and potential team restructuring initiatives ahead.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
ETHAMIDE represents a late-lifecycle career opportunity suitable for professionals focused on defensive marketing, customer retention, and operational efficiency rather than innovation or expansion. Limited headcount and job postings (0 linked roles) suggest this is a maintenance-focused assignment with lower visibility for career advancement.
Brand ManagerProduct Manager
Worked on ETHAMIDE at AbbVie? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.